-
Je něco špatně v tomto záznamu ?
The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer
M. Wenzel, M. Deuker, F. Stolzenbach, L. Nocera, C. Collà Ruvolo, Z. Tian, SF. Shariat, F. Saad, A. Briganti, LA. Kluth, FKH. Chun, PI. Karakiewicz
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- běloši statistika a číselné údaje MeSH
- černoši nebo Afroameričané statistika a číselné údaje MeSH
- Hispánci a Latinoameričané statistika a číselné údaje MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory močové trubice klasifikace mortalita patologie MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: To test the effect of race/ethnicity on histological subtype, stage at presentation, and cancer specific mortality (CSM) in urethral cancer patients. MATERIAL AND METHODS: Stratified analyses (Surveillance, Epidemiology and End Results [2004-2016]) tested the effect of race/ethnicity on histology and stage. Cumulative incidence-plots and multivariable competing-risks regression models (CRR), addressed CSM, after matching for TNM-stage, histology, age, and gender. RESULTS: Of 1,904 urethral cancer patients, 71% were Caucasian, 16% African American, 7% Hispanic and 5% other. African Americans were younger (66 years) than Caucasians (73 years) and Hispanics (74 years). In African Americans, adenocarcinoma (25%) and squamous cell carcinoma (SCC; 29%) were more frequent than in Caucasians (12% and 23%) or Hispanics (15% and 20%). African Americans with adenocarcinoma exhibited higher stage than other adenocarcinoma patients. In CRR, African Americans (35%) and Hispanics (29%) exhibited highest and second highest 3-year CSM, even after matching. After further multivariable adjustment of matched CRRs, CSM was higher in Hispanics (HR: 1.93, P= 0.03) and in African Americans (Hazard ratio 1.35, P= 0.07), relative to Caucasians. CONCLUSION: Race/ethnicity impacts important differences on urethral cancer patients. African American race/ethnicity predisposes to higher rate of SCC and adenocarcinoma. Moreover, African Americans are younger and present with higher stage at diagnoses. Finally, even after most detailed matching for stage, age, gender, and adjustment for treatment and systemic therapy and socioeconomic status, African Americans and Hispanics exhibit higher CSM than Caucasians.
Department of Urology 2nd Faculty of Medicine Charles University Prag Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University Hospital Frankfurt Frankfurt am Main Germany
Department of Urology University of Texas Southwestern Dallas TX
Departments of Urology Weill Cornell Medical College New York NY
Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004307
- 003
- CZ-PrNML
- 005
- 20220228092207.0
- 007
- ta
- 008
- 220113s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.urolonc.2020.11.031 $2 doi
- 035 __
- $a (PubMed)33309509
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Wenzel, Mike $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Electronic address: Mike.Wenzel@kgu.de
- 245 14
- $a The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer / $c M. Wenzel, M. Deuker, F. Stolzenbach, L. Nocera, C. Collà Ruvolo, Z. Tian, SF. Shariat, F. Saad, A. Briganti, LA. Kluth, FKH. Chun, PI. Karakiewicz
- 520 9_
- $a OBJECTIVE: To test the effect of race/ethnicity on histological subtype, stage at presentation, and cancer specific mortality (CSM) in urethral cancer patients. MATERIAL AND METHODS: Stratified analyses (Surveillance, Epidemiology and End Results [2004-2016]) tested the effect of race/ethnicity on histology and stage. Cumulative incidence-plots and multivariable competing-risks regression models (CRR), addressed CSM, after matching for TNM-stage, histology, age, and gender. RESULTS: Of 1,904 urethral cancer patients, 71% were Caucasian, 16% African American, 7% Hispanic and 5% other. African Americans were younger (66 years) than Caucasians (73 years) and Hispanics (74 years). In African Americans, adenocarcinoma (25%) and squamous cell carcinoma (SCC; 29%) were more frequent than in Caucasians (12% and 23%) or Hispanics (15% and 20%). African Americans with adenocarcinoma exhibited higher stage than other adenocarcinoma patients. In CRR, African Americans (35%) and Hispanics (29%) exhibited highest and second highest 3-year CSM, even after matching. After further multivariable adjustment of matched CRRs, CSM was higher in Hispanics (HR: 1.93, P= 0.03) and in African Americans (Hazard ratio 1.35, P= 0.07), relative to Caucasians. CONCLUSION: Race/ethnicity impacts important differences on urethral cancer patients. African American race/ethnicity predisposes to higher rate of SCC and adenocarcinoma. Moreover, African Americans are younger and present with higher stage at diagnoses. Finally, even after most detailed matching for stage, age, gender, and adjustment for treatment and systemic therapy and socioeconomic status, African Americans and Hispanics exhibit higher CSM than Caucasians.
- 650 _2
- $a černoši nebo Afroameričané $x statistika a číselné údaje $7 D001741
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _7
- $a Hispánci a Latinoameričané $x statistika a číselné údaje $7 D006630 $2 czmesh
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádory močové trubice $x klasifikace $x mortalita $x patologie $7 D014523
- 650 _7
- $a běloši $x statistika a číselné údaje $7 D044465 $2 czmesh
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Deuker, Marina $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 700 1_
- $a Stolzenbach, Franziska $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Nocera, Luigi $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Experimental Oncology, Department of Urology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Collà Ruvolo, Claudia $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Italy
- 700 1_
- $a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Departments of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
- 700 1_
- $a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 700 1_
- $a Briganti, Alberto $u Division of Experimental Oncology, Department of Urology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Kluth, Luis A $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 773 0_
- $w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 39, č. 6 (2021), s. 369.e9-369.e17
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33309509 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220228092205 $b ABA008
- 999 __
- $a ok $b bmc $g 1751698 $s 1155456
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 39 $c 6 $d 369.e9-369.e17 $e 20201211 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
- LZP __
- $a Pubmed-20220113
